Peptide Semax OXY-SEMAX (30 mg) OxyPharma

Catalogue entry: Peptide Semax OXY-SEMAX (30 mg) OxyPharma. Labelled content: 30 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Semax is a synthetic peptide derived from an ACTH fragment and modified with an additional short sequence. It is investigated in neurological contexts rather than being equivalent to ACTH itself. Selank is another research peptide often discussed in similar settings, but its sequence and evidence base differ.

What the research measured

Dolotov and colleagues reported BDNF- and trkB-related findings in rat hippocampus in Brain Research in 2006. Human work includes a study of rehabilitation after ischaemic stroke reported by Gusev and colleagues in 2018. A diseased-brain setting and a rodent signalling result do not establish enhanced attention, motivation or sporting decision-making in healthy individuals.

Sporting claims and limitations

Claims about neuroprotection should distinguish a proposed pathway from a meaningful clinical outcome. Study design, accompanying care and formulation all influence interpretation. Long-term human safety and effects in healthy athletes remain incompletely characterised. A peptide's association with a familiar hormone fragment cannot supply a safety guarantee or justify combining several cognitive research compounds.

Product identity and documentation

The selected option records the supplier's labelled quantity and presentation. Useful batch documentation should identify Semax precisely, describe the analytical method and match the actual lot. An article about a particular neurological formulation cannot certify another product's identity, stability or quality. The information here supports careful comparison of research claims rather than a self-treatment plan for concentration or neurological symptoms.